Comprehensive In Silico Analysis of the CXCL12, C55Y Mutation Reveals Structural and Functional Disruption in
Shah Kamal1,2,3, Najeeb Ullah4, Yanjuan Wang1,2,3
1School of Traditional Chinese Medicine, Faculty of Medicine, Yangzhou University, Yangzhou, Jiangsu, China.
Background:
CXCL12 is a critical chemokine involved in immune cell trafficking and tumor metastasis through its interaction with CXCR4 and CXCR7. The C55Y mutation in CXCL12 is hypothesized to disrupt its structure and function. Unlike previously reported CXCL12 mutations that affect transcriptional regulation or single-receptor binding, C55Y targets a conserved cysteine residue essential for a structural disulfide bridge, potentially inducing unique global destabilization. This study investigates the molecular consequences of the C55Y mutation using computational tools.
Objectives:
This study aimed to evaluate the structural and functional impact of the C55Y mutation in CXCL12, particularly its interactions with CXCR4 and CXCR7, and its relevance to prostate cancer pathogenesis.
Methods:
Molecular dynamics simulations (MDS), evolutionary conservation analysis, and molecular docking with CXCR4 and CXCR7 receptors were performed to assess the impact of the C55Y mutation. Tools such as I-TASSER, Meta-SNP, and PolyPhen-2 were used to analyze structural stability, while HDOCK and Schrödinger simulations assessed receptor binding. RMSD and RMSF calculations were used to evaluate protein dynamics.
Results:
The C55Y mutation induces significant structural instability in CXCL12, with increased RMSD and altered secondary structure. Molecular dynamics simulation further demonstrated the stability of the complexes through RMSD, RMSF, hydrogen bond, and Radius of Gyration (RoG) analyses, where the normal complexes exhibited comparatively stable structural compactness during the simulation period. Docking studies showed reduced binding affinity to CXCR4 and CXCR7, indicating disrupted receptor interactions. Notably, this dual-receptor binding loss distinguishes C55Y from other mutations that typically impair only CXCR4 signaling. These findings suggest that the mutation impairs CXCL12's function in prostate cancer, metastasis of prostate cancer, and immune response.
Conclusion:
The C55Y mutation in CXCL12 disrupts its structural integrity and receptor binding, uniquely compromising both the CXCR4 and CXCR7 pathways. This highlights its potential role in prostate cancer progression through mechanisms distinct from previously characterized CXCL12 variants. This study provides insights into the molecular mechanisms of CXCL12-mediated signaling and its implications for future therapeutic strategies targeting chemokine signaling to inhibit prostate cancer.
